GlaxoSmithKline Aktie [ISIN: ARDEUT110483]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu GlaxoSmithKline PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs

07.06.24		US FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk (EN, GlaxoSmithKline)
06.06.24		GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies (EN, GlaxoSmithKline)
03.06.24		Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer (EN, GlaxoSmithKline)
02.06.24		Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
01.06.24		Statement: Zantac (ranitidine) litigation - Delaware State Court Daubert Ruling (EN, GlaxoSmithKline)
23.05.24		Statement: Zantac (ranitidine) litigation - Valadez and Williams cases (EN, GlaxoSmithKline)
21.05.24		GSK announces positive results from phase III severe asthma trials of depemokimab (EN, GlaxoSmithKline)
16.05.24		GSK to become a founding partner of Fleming Initiative to fight antimicrobial resistance (AMR) (EN, GlaxoSmithKline)
01.05.24		GSK makes a strong start to 2024 with improving outlook for the year (EN, GlaxoSmithKline)
17.04.24		EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments (EN, GlaxoSmithKline)
17.04.24		New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade (EN, GlaxoSmithKline)
16.04.24		GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA (EN, GlaxoSmithKline)
16.03.24		Positive RUBY phase III data show potential for Jemperli (dostarlimab) combinations in more patients with primary advanced or recurrent endometrial cancer (EN, GlaxoSmithKline)
07.03.24		GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise (Businesswire)
07.03.24		GSK announces positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
04.03.24		ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses (EN, GlaxoSmithKline)
29.02.24		GSK announces Dr Jeannie Lee to join the Board as Non-Executive Director (EN, GlaxoSmithKline)
29.02.24		Statement: Zantac (ranitidine) litigation (EN, GlaxoSmithKline)
28.02.24		ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV (EN, GlaxoSmithKline)
26.02.24		GSK announces positive headline results from EAGLE-1 phase III trial for gepotidacin in uncomplicated urogenital gonorrhoea (GC) (EN, GlaxoSmithKline)
15.02.24		GSK completes acquisition of Aiolos Bio (EN, GlaxoSmithKline)
12.02.24		GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B (EN, GlaxoSmithKline)
06.02.24		GSK’s RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk (EN, GlaxoSmithKline)
06.02.24		GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk (Businesswire)
06.02.24		GSK’s regulatory application for Shingrix for the prevention of shingles in at-risk adults aged 18 and over accepted for review by China National Medical Products Administration (EN, GlaxoSmithKline)
05.02.24		DREAMM-7 phase III trial shows Blenrep combination nearly tripled median progression-free survival versus standard of care combination in patients with relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
01.02.24		Statement: Zantac (ranitidine) litigation (EN, GlaxoSmithKline)
31.01.24		GSK delivers strong 2023 performance and upgrades growth outlooks (EN, GlaxoSmithKline)
29.01.24		GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency for the prevention of RSV disease in adults aged 50-59 at increased risk (EN, GlaxoSmithKline)
29.01.24		European Commission authorises GSK’s Omjjara (momelotinib) (EN, GlaxoSmithKline)
10.01.24		Nucala (mepolizumab) approved in China for use in severe asthma with an eosinophilic phenotype (EN, GlaxoSmithKline)
09.01.24		GSK enters agreement to acquire Aiolos Bio (EN, GlaxoSmithKline)
20.12.23		GSK enters exclusive license agreement with Hansoh for HS-20093 (EN, GlaxoSmithKline)
18.12.23		Jemperli (dostarlimab) plus Zejula (niraparib) combination significantly improved progression-free survival in primary advanced or recurrent endometrial cancer in RUBY Part 2 Phase III trial (EN, GlaxoSmithKline)
12.12.23		GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity (Businesswire)
12.12.23		Japan’s Ministry of Health, Labour and Welfare accepts Arexvy (RSV vaccine) regulatory application to prevent RSV disease in adults aged 50-59 at increased risk (EN, GlaxoSmithKline)
11.12.23		GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the first and only frontline immuno-oncology treatment in the European Union for dMMR/MSI-H primary advanced or recurrent endometrial cancer (EN, GlaxoSmithKline)
06.12.23		New global analysis across five cities shows inequities in adult immunisation uptake, signalling need to redesign local and national policy interventions (EN, GlaxoSmithKline)
30.11.23		New global survey finds widespread misunderstandings about shingles despite its lifetime prevalence (EN, GlaxoSmithKline)
27.11.23		GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep in relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
22.11.23		GSK announces major step towards sustainability ambitions with advancement of low carbon Ventolin programme to Phase III trials (EN, GlaxoSmithKline)
13.11.23		GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative (Businesswire)
25.10.23		New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease (Businesswire)
05.09.23		GSK and Earvin "Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations (Businesswire)
17.08.23		GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies (Businesswire)
31.07.23		Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer (Businesswire)
13.07.23		GSK is first to ship influenza vaccine doses for the 2023-24 flu season in US (Businesswire)
21.06.23		GSK shares positive data for AREXVY, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons (Businesswire)
20.06.23		GSK and Lifetime® Release Short Film Featuring Soleil Moon Frye and Melissa Joan Hart Urging Parents to "Ask2BSure” about Meningitis B (Businesswire)
01.06.23		GSK Announces the COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the US (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Ripple explodiert – Jetzt investieren und Millionär werden?

DHL und Diageo setzen auf Nikola - Wasserstoff-Mobilität

Solana überholt Ethereum – Alle Details im Überblick

OMV-Aktie steigt: Preise trotz Gas-Lieferstopps von Gazprom an die OMV vorerst stabil

Siemens Energy-Aktie leichter nach neuem Rekord: Goldman Sachs und JPMorgan haben Ziele für Siemens Energy angehoben

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	20.11.2024 07:16
Kaufwert:	EUR
	Hinzufügen Speichern